Ultragenyx Pharmaceutical Inc. (RARE) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Ultragenyx Pharmaceutical Inc. (RARE) closed at USD 14.90 on 2026-10-14, a change of -57.1 % over the past year, with a market capitalization of USD 1.5B.

Ultragenyx Pharmaceutical Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Ultragenyx Pharmaceutical Inc. key figures

Previous close

USD 14.90 (2026-10-14)

1-year change

-57.1 %

Market cap

USD 1.5B

Enterprise value

USD 2.41B

P/E ratio (trailing)

-2.56

P/E ratio (forward)

67.25

EPS (trailing)

-5.92

EPS (forward)

0.23

PEG ratio

n/a

Price to book

-5.13

Revenue growth

28.1 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.95

Employees

1,371

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Ultragenyx Pharmaceutical Inc. and compare it with other stocks.